Generic Imatinib in Chronic Myeloid Leukemia: Survival of the cheapest

Conclusion: The findings of the present study showed comparable efficacy and safety of the generic and innovator versions of imatinib in the treatment of patients with CML. Teaser The results of a retrospective analysis, of data from a large group patients with chronic myeloid leukemia (CML) treated with frontline Imatinib mesylate (Innovator/Generic) at a single institution between 2008 and 2014 showed comparable efficacy and safety.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research